SCHEMBL4572145

SCHEMBL4572145

C#Cc1nc(N)c2ncn(CCC)c2n1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA2A P29274 7/20 0.56
ADORA1 P30542 5/20 0.56
ADORA2B P29275 2/20 0.56
TMIGD3 P0DMS9 3/20 0.52
CDK1 P06493 2/20 0.50
CCNB1 P14635 2/20 0.50
CCNE1 P24864 2/20 0.50
CDK2 P24941 2/20 0.50
CYP2C19 P33261 2/20 0.43
CTSL P07711 1/20 0.43
CTSB P07858 1/20 0.43
ALDH1A1 P00352 1/20 0.42
CYP1A2 P05177 1/20 0.41
CYP3A4 P08684 1/20 0.41
CYP2D6 P10635 1/20 0.41
CYP2C9 P11712 1/20 0.41
HIF1A Q16665 1/20 0.41
PI4KA P42356 1/20 0.41
PI4K2B Q8TCG2 1/20 0.41
PI4K2A Q9BTU6 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14401041 0.88 CDK1 (0.65) ADORA2AADORA1ADORA2BTMIGD3CDK1
SCHEMBL14145054 0.83 ADORA2A (0.58) ADORA2AADORA1CDK1CCNB1CCNE1
SCHEMBL14145481 0.82 CDK1 (0.45) ADORA2AADORA1ADORA2BTMIGD3CDK1
SCHEMBL19553535 0.82 ADORA2A (0.53) ADORA2AADORA1CDK1CCNB1CCNE1
SCHEMBL179439 0.82 PI4KA (0.57) ADORA2AADORA1ADORA2BTMIGD3CDK1
SCHEMBL12417531 0.80 CDK1 (0.58) ADORA2AADORA1ADORA2BCDK1CCNB1
SCHEMBL1377647 0.80 CDK1 (0.76) ADORA2AADORA1ADORA2BTMIGD3CDK1
SCHEMBL232387 0.79 ADORA2A (0.62) ADORA2AADORA1ADORA2BTMIGD3CDK1
SCHEMBL26225613 0.78 ADORA2A (0.48) ADORA2ACDK1CCNB1CCNE1CDK2
SCHEMBL24980488 0.78 ADORA2A (0.60) ADORA2AADORA1ADORA2BTMIGD3CDK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120149701-A1 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS INTELLIKINE, INC. 2012-06-14 US disclosed
US-8193182-B2 Substituted isoquinolin-1(2H)-ones, and methods of use thereof INTELLIKINE, INC. (US) 2012-06-05 US disclosed
US-20120122838-A1 HETEROCYCLIC COMPOUNDS AND USES THEREOF INFINITY PHARMACEUTICALS, INC. 2012-05-17 US disclosed
US-20120059000-A1 CHEMICAL COMPOUNDS, COMPOSITIONS AND METHODS FOR KINASE MODULATION INFINITY PHARMACEUTICALS, INC. 2012-03-08 US disclosed
US-20110046165-A1 CERTAIN CHEMICAL ENTITLES, COMPOSITIONS AND METHODS INTELLIKINE LLC 2011-02-24 US disclosed
US-20070244134-A1 Selective antagonists of A2A adenosine receptors ADENOSINE THERAPEUTICS, LLC 2007-10-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120059000-A1 CHEMICAL COMPOUNDS, COMPOSITIONS AND METHODS FOR KINASE MODULATION MAP3K13, AKT3, PIK3CA ADORA2A 1787/4885ADORA1 2434/4885ADORA2B 2523/4885
US-20120122838-A1 HETEROCYCLIC COMPOUNDS AND USES THEREOF PIK3CA, PIK3CD, PIK3CB ADORA2A 1165/4885ADORA1 2514/4885ADORA2B 2605/4885
US-20070244134-A1 Selective antagonists of A2A adenosine receptors ADORA2A, ADORA1, ADORA2B ADORA2A 1/4885ADORA1 2/4885ADORA2B 3/4885
US-20120149701-A1 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS PIK3CA, AKT3, PIK3C2A ADORA2A 1252/4885ADORA1 1782/4885ADORA2B 1523/4885
US-20110046165-A1 CERTAIN CHEMICAL ENTITLES, COMPOSITIONS AND METHODS PIK3CA, AKT3, PIK3C2A ADORA2A 1051/4885ADORA1 1525/4885ADORA2B 1485/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.